Tapentadol extended release (ER) + Oxycodone controlled release (CR)
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful
Conditions
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
Trial Timeline
Jan 1, 2010 → Jun 1, 2010
NCT ID
NCT01063868About Tapentadol extended release (ER) + Oxycodone controlled release (CR)
Tapentadol extended release (ER) + Oxycodone controlled release (CR) is a phase 3 stage product being developed by Johnson & Johnson for Diabetic Neuropathy, Painful. The current trial status is terminated. This product is registered under clinical trial identifier NCT01063868. Target conditions include Diabetic Neuropathy, Painful, Diabetic Polyneuropathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01063868 | Phase 3 | Terminated |
Competing Products
20 competing products in Diabetic Neuropathy, Painful